Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug;32(8):713-734.
doi: 10.1007/s40263-018-0556-y.

Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents

Affiliations
Free PMC article
Review

Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents

Richard E Frye. CNS Drugs. .
Free PMC article

Abstract

Autism spectrum disorder is defined by two core symptoms: a deficit in social communication and the presence of repetitive behaviors and/or restricted interests. Currently, there is no US Food and Drug Administration-approved drug for these core symptoms. This article reviews the biological origins of the social function deficit associated with autism spectrum disorder and the drug therapies with the potential to treat this deficit. A review of the history of autism demonstrates that a deficit in social interaction has been the defining feature of the concept of autism from its conception. Abnormalities identified in early social skill development and an overview of the pathophysiology abnormalities associated with autism spectrum disorder are discussed as are the abnormalities in brain circuits associated with the social function deficit. Previous and ongoing clinical trials examining agents that have the potential to improve social deficits associated with autism spectrum disorder are discussed in detail. This discussion reveals that agents such as oxytocin and propranolol are particularly promising and undergoing active investigation, while other agents such as vasopressin agonists and antagonists are being activity investigated but have limited published evidence at this time. In addition, agents such as bumetanide and manipulation of the enteric microbiome using microbiota transfer therapy appear to have promising effects on core autism spectrum disorder symptoms including social function. Other pertinent issues associated with developing treatments in autism spectrum disorder, such as disease heterogeneity, high placebo response rates, trial design, and the most appropriate way of assessing effects on social skills (outcome measures), are also discussed.

Conflict of interest statement

Richard E. Frye has no conflicts of interest directly relevant to the contents of this article.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, Kurzius-Spencer M, Zahorodny W. Robinson Rosenberg C, White T, Durkin MS, Imm P, Nikolaou L, Yeargin-Allsopp M, Lee LC, Harrington R, Lopez M, Fitzgerald RT, Hewitt A, Pettygrove S, Constantino JN, Vehorn A, Shenouda J, Hall-Lande J, Van Naarden Braun K, Dowling NF. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 Sites, United States, 2014. MMWR Surveill Summ. 2018;67(6):1–23. doi: 10.15585/mmwr.ss6706a1. - DOI - PMC - PubMed
    1. Evans B. How autism because autism: the radical transformation of a central concept of child development in Britain. Hist Human Sci. 2013;26(3):3–31. doi: 10.1177/0952695113484320. - DOI - PMC - PubMed
    1. Piaget J. Symbolic thought and infantile thought. Arch Psychol. 1923;18:273–304.
    1. Kanner L. Autistic disturbances of affective contact. Nervous Child. 1943;2:217–250.
    1. Asperger H. Die, “Autistischen Psychopathen” im Kindesalter. Archiv Psychiatrie Nervenkrankheiten. 1944;117(1):76–136. doi: 10.1007/BF01837709. - DOI

MeSH terms

Substances

Feedback